S&P 500 Industrials Sector SEC Filings — April 07, 2026

07-04-2026

Pioneer Bancorp, Inc. issued a definitive proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on May 19, 2026 at 9:00 a.m. local time, soliciting votes for the election of three directors, ratification of Bonadio & Co., LLP as independent registered public accounting firm for the year ending December 31, 2026, and a non-binding advisory resolution on Named Executive Officers' compensation. As of the record date March 23, 2026, there were 25,076,801 shares of common stock outstanding, with Pioneer Bancorp, MHC beneficially owning 14,287,723 shares (57.0%) and M3 Funds, LLC owning 1,884,081 shares (7.5%). The Board unanimously recommends voting 'FOR' all proposals, and no directors or executive officers have pledged shares.

• ·Record date for voting eligibility: March 23, 2026
• ·Virtual annual meeting access: https://www.cstproxy.com/pioneerbancorp/2026 (requires 12-digit control number)
• ·Registration deadline for beneficial owners to attend virtually: 5:00 p.m. ET on May 14, 2026
• ·Conference call for listening: +1-800-450-7155 (U.S./Canada toll-free) or +1-857-999-9155 (international), code 4849410#
• ·Articles of Incorporation limit voting rights for holders >10% (except Pioneer Bancorp, MHC)

07-04-2026

Target Hospitality Corp.'s DEF 14A proxy statement seeks stockholder approval for the election of six director nominees at the annual meeting on May 21, 2026. It highlights strong 2025 fiscal year performance, including $320.6 million in total revenue, $53.2 million in Adjusted EBITDA, $66 million in Discretionary Cash Flow, $0 net debt, and ~$740 million in new multi-year awards secured since February 2025, supported by 16,991 beds across 29 communities. The company emphasizes robust corporate governance, stockholder outreach engaging over 80% of shares, and a skilled board with expertise in leadership, operations, finance, and strategy.

• ·Annual meeting scheduled for May 21, 2026
• ·Fiscal year ended December 31, 2025
• ·Board competencies: 6 directors with advanced/expert leadership/business head/administration, business operations, corporate governance, finance/capital allocation/risk management, strategy; 5 with safety, human resources/talent management, board/committee experience; 4 with financial expertise/literacy, government/public policy, M&A/capital markets; 2 with marketing/sales, cybersecurity/IT; 1 with AI data centers/critical infrastructure

07-04-2026

Legato Merger Corp. III is seeking shareholder approval via proxy for an Extension Proposal to amend its memorandum and articles, extending the deadline to complete its initial business combination with Einride beyond May 8, 2026, to avoid liquidation and redemption of public shares. Officers and directors, owning 4,356,475 ordinary shares (16.3% of outstanding shares), intend to vote in favor of the Extension and Adjournment Proposals. Public shareholders retain redemption rights at an estimated $11.00 per share, with potential Insiders' purchases to reduce redemptions, though no such plans are committed.

• ·Extension Proposal requires special resolution (at least two-thirds majority of votes cast).
• ·Adjournment Proposal requires ordinary resolution (simple majority of votes cast).
• ·If Extension not approved, liquidation by May 8, 2026, with public shares redeemed from Trust Account (net of taxes and up to $100,000 dissolution expenses).
• ·Company may seek further extensions if deemed in best interests.
• ·Insiders may purchase Public Shares at <= $11.00/share pre/post-meeting to reduce redemptions, but such shares would not be voted.

07-04-2026

The U.S. Bankruptcy Court for the Southern District of Texas confirmed the Fourth Amended Chapter 11 Plan of Liquidation for Luminar Technologies, Inc. and its four affiliated debtors on April 3, 2026, following a confirmation hearing on April 1, 2026, with all objections overruled. The debtors filed voluntary Chapter 11 petitions on December 15 and 31, 2025 (Case No. 25-90807), and have operated as debtors in possession since then. The plan proceeds to liquidation, marking a significant adverse development with no ongoing operations highlighted.

• ·Chapter 11 Cases jointly administered under Case No. 25-90807 (CML) in the Southern District of Texas Houston Division
• ·Creditors’ Committee appointed by U.S. Trustee on December 30, 2025
• ·Debtors’ mailing address: 2603 Discovery Drive, Suite 100, Orlando, Florida 32826
• ·Confirmation Hearing held April 1, 2026; Voting and Objection Deadline March 23, 2026

07-04-2026

Opus Genetics announced a strategic financing agreement with Oberland Capital providing up to $155 million in non-dilutive funding via notes, including an initial $35 million tranche and a concurrent $5 million equity investment at $4.48 per share, boosting current cash to approximately $100 million and extending the runway into 2029 to fund pivotal studies for OPGx-LCA5 and OPGx-BEST1. The deal supports accelerating three earlier-stage programs—OPGx-RDH12 (clinic Q4 2026), OPGx-MERTK (end 2026), and OPGx-RHO (2027)—with topline results from OPGx-BEST1 Phase 1/2 Cohort 1 on track for mid-2026. No declines or flat metrics reported; financing terms include 7-year maturity, ~4.1% initial cash interest rate, and partial convertibility.

• ·Initial closing expected April 20, 2026; notes mature 7 years from issuance with 6-year interest-only period and 50% repayment on 6th anniversary.
• ·Notes: floating rate with floor/cap; 50% interest paid-in-kind first 8 quarters; up to 10% principal convertible at $6.72/share.
• ·Additional $35M tranche available on or prior to March 31, 2028 upon LCA5 regulatory milestones.
• ·RDH12 partially funded by RDH12 Alliance; MERTK collaboration with Department of Health - Abu Dhabi.

07-04-2026

Janus Henderson Group plc filed definitive additional materials (DEFA14A) on April 7, 2026, supplementing the proxy statement for the special shareholder meeting on April 16, 2026, to approve the merger with Jupiter Company Limited and Jupiter Merger Sub Limited under the amended Agreement and Plan of Merger dated December 21, 2025. The supplement adds disclosures to the merger background, detailing competing non-binding proposals including Trian/General Catalyst's $46.00 per share cash offer (October 26, 2025) and Victory Capital's $50-$52 per share mixed cash/stock proposals, which were diligenced but not advanced. It also updates unaudited prospective financial information showing steady revenue growth from $2,134 million in 2025E to $2,671 million in 2029E and EBITDA from $786 million to $1,048 million, with no declines noted across projections.

• ·Special meeting scheduled for 9:00 a.m. Denver time on April 16, 2026, at 151 Detroit Street, Denver, CO 80206.
• ·Merger agreement amended by Amendment No. 1 on March 24, 2026.
• ·Supplemental disclosures made to address litigation risks without admitting liability.
• ·Victory Capital proposals conditioned on due diligence, shareholder approvals, and client consents.
• ·Projections assume 5% annual portfolio value increase (2026-2029) and 3% expense inflation.

07-04-2026

S&T Bancorp, Inc. and S&T Bank entered into an amended and restated employment agreement with CEO Christopher McComish, effective January 1, 2026, for a four-year term with automatic annual renewals. The agreement sets a minimum annual base salary of $785,000, target annual bonus of 67% of base salary, and long-term incentive awards with target value of at least 100% of base salary (50% time-vesting, 50% time- and performance-vesting). It includes severance of 2x (or 3x within two years post-change in control) base plus target bonus, COBRA premiums for 24 (or 36) months, and other perks like up to $25,000 annual vehicle allowance and $25,000 legal fee reimbursement, plus one-year post-termination non-compete and non-solicit covenants.

• ·Employment agreement has a four-year initial term with automatic one-year renewals.
• ·Severance benefits conditioned on execution of a release of claims.
• ·Perpetual covenants for nondisclosure of confidential information and non-disparagement.
• ·Non-competition and non-solicitation covenants apply for one year post-termination.

07-04-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on April 7, 2026, disclosing a press release announcing that its RAD division is implementing its first hardware price increase in nearly three years due to market conditions demanding adjustment. The press release is attached as Exhibit 99.1 and furnished under Item 8.01, not deemed filed or material.

• ·Filing explicitly states information is furnished, not filed, and not deemed material.
• ·Date of earliest event reported: April 7, 2026.

07-04-2026

NXG NextGen Infrastructure Income Fund issued a Notice of Guaranteed Delivery (EX-99.1) for its rights offering under the Prospectus Supplement dated April 6, 2026, and accompanying Prospectus dated July 9, 2025. The form facilitates subscription for common shares via primary subscription and over-subscription privilege, with submissions required by 5:00 p.m. ET on the Expiration Date of April 30, 2026, to Subscription Agent Equiniti Trust Company, LLC. No financial performance metrics or period comparisons are provided in the filing.

• ·Subscription delivery addresses: 55 Challenger Road, Suite #200, Ridgefield Park, New Jersey 07660, Attn: Reorganization Department
• ·Information Agent contact: (800) 207-2872
• ·Guaranteed delivery must be followed by Subscription Certificate by close of business on the first business day after Expiration Date

07-04-2026

InTrack Investment Management Inc. filed its 13F-HR report disclosing total equity holdings of $175,479,569 as of March 31, 2026, across 108 positions in stocks and ETFs. Top holdings include iShares Core S&P 500 ETF ($6,978,039), Fidelity Covington Trust Enhanced International ($6,498,851), Apple Inc. ($6,379,565), and iShares 3-7 Year Treasury Bond ETF ($5,985,432). The portfolio is managed by Myron Sopher, Managing Partner and CCO, based in South Burlington, VT.

• ·Report filed on April 07, 2026 for period ending March 31, 2026
• ·All holdings reported as sole voting authority
• ·Business address: 1233 Shelburne Road, Suite D6B, South Burlington, VT 05403
• ·SEC file number: 028-21062

07-04-2026

Protagenic Therapeutics, Inc. notified Alexander Arrow, MD, its Chief Financial Officer, that his employment will be terminated effective April 30, 2026, with the board notification occurring on March 31, 2026. No replacement has been announced, representing a key leadership transition. The filing was signed by Executive Chairman Garo H. Armen.

• ·Filing signed on April 6, 2026, and dated April 7, 2026

07-04-2026

Sphere 3D Corp. is seeking shareholder approval at a special virtual meeting for the acquisition of Cathedra via an Arrangement Agreement, involving the issuance of approximately 4,203,089 Sphere Common Shares (42% of outstanding on a fully diluted basis), resulting in former Sphere shareholders owning 58% and former Cathedra shareholders 42% of the combined company post-transaction. Additional proposals include fixing the board size at five directors, electing five new director nominees, amending the incentive plan to increase available shares from 639,252 to 2,139,252 (adding 1,500,000 shares), and authorizing a potential share consolidation on a 1-for-up to 5 basis, which introduces dilution risk but aims to enhance capital structure flexibility. Completion of the Arrangement requires approvals for share issuance, board size, director election, and incentive plan, plus court and regulatory approvals, but is not conditioned on consolidation.

• ·Special meeting held virtually; quorum requires 33 1/3% of shares present.
• ·Share Issuance, Board Size, Director Election, and Incentive Plan require majority of votes cast; Consolidation requires 2/3 of votes cast.
• ·Arrangement not conditioned on Consolidation approval.
• ·References financials in 2025 10-K and subsequent 10-Qs available on SEC and Sphere website.

07-04-2026

Baring Financial LLC filed its 13F-HR on April 7, 2026, reporting holdings as of March 31, 2026, with a total portfolio value of $163480928 across 72 positions held solely on a discretionary basis. The portfolio emphasizes ETFs such as iShares Core S&P 500 ETF valued at $15796176 and Schwab Strategic TR US LCAP VA ETF at $7180193, alongside individual stocks including Berkshire Hathaway Inc. DEL CL B NEW at $4873943, Apple Inc. at $2835160, and NVIDIA Corporation at $2865400. No changes in holdings were indicated in the filing.

• ·Filing CIK: 0002052588
• ·Filer address: 1310 10th Street Suite 101, Bellingham, WA 98225
• ·All positions reported with sole discretionary voting authority and no indicated additions, reductions, or other changes

07-04-2026

Versant Capital Management, Inc. filed a 13F-HR report disclosing institutional equity holdings totaling exactly 1014401343 USD across 2777 positions as of March 31, 2026. Top positions include Vanguard Total Stock Market ETF at 11808367 USD (36808 shares), Amazon.com Inc. at 7821254 USD (37553 shares), and iShares Gold Trust ETF at 6058972 USD (68727 shares), representing a highly diversified portfolio with no dominant concentration. The filing, signed by Brandon Yee (Director of Research), shows sole voting/dispositive power over all listed holdings with no other managers reported.

• ·Filing submitted on 2026-04-07 for period ending 2026-03-31
• ·All holdings reported with sole voting and dispositive power (SH SOLE column values match shares)
• ·Filer CIK: 0001735057, based in Phoenix, AZ

07-04-2026

Rosenberg Matthew Hamilton filed a 13F-HR on April 7, 2026, disclosing sole discretionary holdings as of March 31, 2026, in a diversified portfolio emphasizing ETFs and individual stocks. Top positions include Vanguard Total Stock Market ETF (45382127 USD market value, 141461 shares), Vanguard Intermediate-Term Corporate Bond ETF (39262227 USD, 474468 shares), and JPMorgan Ultra-Short Income ETF (36313681 USD, 717520 shares), with additional exposure to stocks like Microsoft (7442 shares), Ford Motor (15636 shares), and Starbucks (3355 shares). The portfolio features no reported changes, puts, or calls across 200+ positions spanning U.S. equities, bonds, international, and commodities.

• ·Filing CIK: 0001812103
• ·SEC File Number: 028-20259
• ·Address: 200 Grand Avenue, Ste. 205, Grand Junction, CO 81501
• ·Phone: 9707735300
• ·Over 200 positions reported, all sole discretionary with no puts/calls

07-04-2026

Janus Detroit Street Trust filed DEFA14A soliciting U.S. mutual fund and ETF shareholders to vote on a new investment advisory agreement with Janus Henderson, required due to the pending take-private transaction with Trian and General Catalyst. The Boards of Trustees recommend voting FOR approval, emphasizing no changes to investment teams, processes, or portfolio management. Shareholders can vote online, by phone, or mail.

• ·Filing Date: April 07, 2026
• ·Voting options: Online (www.votejhi.com/mutualfunds for mutual funds, www.votejhi.com/ETFs for ETFs), Phone (Mutual Funds: +1-855-206-2338; ETFs: +1-855-206-2309), or Mail via proxy card

07-04-2026

Seilern Investment Management Ltd filed a 13F-HR disclosing 24 equity positions totaling $838486413 as of March 31, 2026. Top holdings include Mastercard Incorporated ($88921992), UnitedHealth Group Inc ($76067990), Tyler Technologies Inc ($62401494), West Pharmaceutical Services Inc ($56649903), and Edwards Lifesciences Corp ($55270495), all held with sole voting authority. No prior period comparisons are provided in the filing.

• ·Filing date: April 07, 2026
• ·Report period end: March 31, 2026
• ·Filer address: Burdett House, 15-16 Buckingham Street, London X0 WC2N 6DU
• ·All holdings reported with sole shared discretion and sole voting authority

07-04-2026

GT Biopharma, Inc. entered into an Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota on April 3, 2026, under which the University will sponsor an IND application (IND 169118) for GTB-5550 and conduct a phase 1a/1b clinical trial titled 'GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy.' The Company will bear the costs of up to approximately $3.8 million over three years for the study, with both parties having rights to publish results and standard termination provisions including 30 days' notice or immediate for safety reasons.

• ·IND number: 169118
• ·Agreement termination: 30 days' written notice, immediate by University for health/safety, or for material breach uncured within 30 days

07-04-2026

Kiora Pharmaceuticals closed a private placement on April 6, 2026, providing up to $24 million in gross proceeds, including $5.0 million upfront funding from sole investors Perceptive Advisors (new) and ADAR1 Capital Management, with up to an additional $19 million upon exercise of milestone-based warrants. Proceeds will support general corporate purposes, business operations, strategic business development, and ongoing R&D for retinal disease therapies like KIO-301 and KIO-104. The transaction was priced at-the-market under Nasdaq rules with no placement agent engaged.

• ·Tranche A-1 warrants: initial 9-month term, reduces to 30 days upon strategic transaction expanding market opportunity.
• ·Tranche A-2 warrants: initial 4-year term, reduces to 30 days upon any asset completing Phase 3 enrollment.
• ·Pre-funded warrants issued in lieu of common stock at $2.543 minus $0.0001 exercise price.
• ·Company to file SEC registration statement for resale of shares and warrant shares.
• ·Transaction closed April 6, 2026, under Section 4(a)(2)/Regulation D; securities unregistered.

07-04-2026

Passage Bio, Inc. has issued definitive additional proxy materials for its 2026 Annual Meeting of Stockholders, to be held virtually on May 19, 2026, at 9:00 AM ET. Stockholders are asked to vote on electing two Class III directors (Athena Countouriotis, M.D. and Sandip Kapadia), ratifying KPMG LLP as independent auditors for the fiscal year ending December 31, 2026, approving executive compensation on an advisory basis, and approving a one-year frequency for future advisory votes on compensation. Votes must be submitted by May 18, 2026, 11:59 PM ET, via www.ProxyVote.com.

• ·Meeting held virtually at www.virtualshareholdermeeting.com/PASG2026.
• ·Proxy materials available online; paper/email requests due by May 5, 2026.
• ·Board recommends 'For' on Proposals 1-3 and '1 Year' on Proposal 4.

07-04-2026

GEE Group Inc. (NYSE American: JOB) filed an 8-K on April 7, 2026, furnishing an investor presentation dated April 6, 2026, under Item 7.01 to describe the Company's business to stockholders. The presentation is attached as Exhibit 99.1 and is not deemed filed for liability purposes under the Exchange Act. No specific financial metrics or performance data are disclosed in the filing itself.

• ·Date of earliest event reported: April 6, 2026
• ·Filing signed by Kim Thorpe on April 7, 2026

07-04-2026

Terns Pharmaceuticals' Board recommends the tender offer and merger with Purchaser (a Merck subsidiary) at $53.00 per share, supported by fairness opinions from Centerview Partners LLC and Jefferies LLC dated March 24, 2026, based on February Management Projections showing minimal revenue ($2M) and losses through 2029E (Net Income -$248M), ramping to peak Net Income of $3,404M in 2042E before declining to $1,757M in 2046E. Projections for TERN-701 assume 45% market penetration at peak sales but include significant early-stage risks and no effect from the transaction. The January Projections are similar but slightly higher at peaks (e.g., 50% penetration assumption).

• ·Projections developed standalone without transaction effects and not updated post-Merger Agreement execution on or before March 24, 2026.
• ·Fairness opinions address only the $53.00 per share consideration's fairness to non-excluded shareholders, not other transaction terms.
• ·Auditor reports for year ended December 31, 2025 cover historical financials only, not projections.

07-04-2026

Capital Bancorp, Inc. (CBNK) filed its DEF 14A proxy statement dated April 7, 2026, for the 2026 Annual Meeting on May 28, 2026, proposing the election of four Class III directors (Jerome R. Bailey, Marc McConnell, Steven J. Schwartz, James F. Whalen) and one Class II director (Mark Caplan), a non-binding advisory vote to approve named executive officer compensation, and ratification of Elliott Davis, PLLC as independent auditor for fiscal year 2026. As of the March 30, 2026 record date, 16,309,270 shares of common stock were issued and outstanding, with the Board recommending a 'FOR' vote on all proposals. No financial performance metrics or period-over-period changes are detailed in the provided content.

• ·Annual Meeting time and location: 5:00 P.M. local time at 2275 Research Blvd., Suite 110 - Conference Center, Rockville, Maryland 20850.
• ·Proxy materials to be mailed on or about April 14, 2026; available online at http://www.astproxyportal.com/ast/22094 and www.capitalbankmd.com.
• ·Voting requires majority of votes cast for director elections and advisory proposals; quorum is majority of outstanding shares.
• ·Corporate address: 2275 Research Blvd., Suite 600, Rockville, Maryland 20850; Investor Relations phone: 301-468-8848.

07-04-2026

Global Net Lease, Inc. filed Definitive Additional Materials (DEFA14A) on April 07, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing is marked as definitive additional proxy materials submitted by the registrant with no fee required. No specific proxy details, financial metrics, or shareholder proposals are included in the provided content.

07-04-2026

KRM Wealth Management L.L.C. filed a 13F-HR report disclosing $182,365,375 in total holdings value across 40 positions as of December 31, 2025. The portfolio is diversified with significant allocations to ETFs, including top holdings such as SCHWAB STRATEGIC TR US LCAP GR ETF ($25,839,886), VANGUARD BD INDEX FDS TOTAL BND MRKT ($25,365,437), SCHWAB STRATEGIC TR US LCAP VA ETF ($23,786,820), and VANGUARD TAX-MANAGED FDS VAN FTSE DEV MKT ($21,382,501). No prior period data is available for comparison.

• ·Filing date: April 07, 2026
• ·Report period end: December 31, 2025
• ·Business address: 3748 Lakeside Dr, Suite 100, Reno, NV 89509
• ·Contact phone: 775-502-8484 or 775-771-9577

07-04-2026

Avidbank Holdings, Inc. (AVBH) filed a DEFA14A Definitive Additional Proxy Materials on April 07, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive financial or operational updates are provided in the filing header.

07-04-2026

Phoenix Education Partners reported Q2 FY2026 revenue of $222.5 million, slightly down 0.4% YoY from $223.4 million, while Average Total Degreed Enrollment rose 1.9% YoY to 82,600; net income fell sharply 33% YoY to $10.8 million due to IPO-related share-based compensation, but Adjusted EBITDA increased 7.7% YoY to $34.8 million. For the first six months of FY2026, revenue grew 1.4% YoY to $484.5 million with enrollment up 3% YoY to 84,100, though net income declined significantly to $26.2 million while Adjusted EBITDA rose 7.4% YoY to $110.0 million. The company announced a $0.21 per share dividend and a $50 million share repurchase program.

• ·Q2 FY2026 diluted EPS of $0.28 vs $0.43 in Q2 FY2025; Adjusted diluted EPS $0.58 vs $0.56.
• ·First six months FY2026 diluted EPS $0.68 vs $1.66; Adjusted diluted EPS $1.97 vs $1.92.
• ·Regular common stock cash dividend of $0.21 per share paid in Q2 FY2026; next payable May 22, 2026 to record date April 29, 2026.
• ·Cash generated by operating activities $80.0 million, capital expenditures $10.1 million as of Feb 28, 2026.
• ·IPO on Oct 10, 2025: 4.9 million shares at $32.00 per share; no proceeds to company.
• ·$100.0 million senior secured revolving credit facility entered Nov 13, 2025, maturing Nov 13, 2030; no outstanding debt.

07-04-2026

Collegium Pharmaceutical achieved record 2025 revenue of $780.6M, with Jornay PM® growing 48% YoY to $148.9M on 20% prescription growth and the pain portfolio up 6% YoY to $631.7M (Nucynta® +11%, Belbuca® +5%, Xtampza® ER +4%). The company generated $329.3M in operating cash flow, held $386.7M in cash and marketable securities, closed a $980M credit facility in December 2025, and repurchased $25M in shares. Board updates included Gino Santini as Chairman and additions of Nancy Lurker and Dr. Carlos Paya, alongside new executive hires.

• ·Jornay PM® prescriber adoption reached an all-time high in 2025.
• ·Headquarters located at 100 Technology Center Drive, Suite 300, Stoughton, MA 02072.

07-04-2026

Civista Bancshares, Inc. filed its DEF 14A Proxy Statement on April 7, 2026, detailing board committee compositions and activities for 2025, including the Compensation Committee (5 members, 3 meetings) and Board Risk Committee (7 members, 4 meetings). Non-employee directors received $1,750 per Bank board meeting, $600 per committee meeting ($1,600 for chairs), and a $20,000 annual retainer paid entirely in common shares for Bank board service from April 15, 2025, to May 19, 2026. No directors elected to defer fees under the non-qualified Deferred Compensation Plan in 2025.

• ·Board Risk Committee established in July 2023 to oversee risk appetite and ERM Policy covering credit, market, liquidity, compliance, operational, legal, reputational, and strategic risks.
• ·Audit Committee oversees independent auditors and material related party transactions.
• ·Compensation Committee approves executive officer compensation and benefit programs.

07-04-2026

Canadian Derivatives Clearing Corporation (CDCC) filed an 8-K on April 7, 2026, under Item 9.01, attaching Exhibit 99.1, which lists the underlying interests for options listed on the Montreal Exchange and offered for sale in the United States pursuant to its Form S-20 Registration Statement, as of March 31, 2026. The exhibit details equity options on numerous Canadian companies (e.g., 5N Plus Inc., Air Canada, Bank of Montreal), index options (e.g., S&P/TSX 60), options on closed-end funds (e.g., Sprott Physical Gold Trust), Canadian Depositary Receipts (CDRs) for U.S. stocks (e.g., Nvidia CDR, Tesla CDR), and various ETFs (e.g., BMO S&P/TSX Capped Composite Index ETF). No financial performance metrics, changes, or comparisons are reported; this appears to be a routine regulatory update with no notable positive or negative developments.

• ·Filing discloses no changes to prior lists; routine update as of March 31, 2026.
• ·Options offered pursuant to CDCC’s Registration Statement on Form S-20.

07-04-2026

The proxy statement announces annual shareholder meetings for abrdn Global Premier Properties Fund (NYSE: AWP), along with AGD and AOD, on May 27, 2026, at 9:00 a.m. ET to elect two Class III Trustees, Christian Pittard and Nancy Yao, each to serve until the 2029 annual meeting. The record date is April 1, 2026, with 30,629,549 shares of AWP outstanding; no financial performance metrics or changes are discussed.

• ·Meetings held at 1900 Market Street, Suite 200, Philadelphia, PA 19103.
• ·Proxy materials available at http://www.aberdeenawp.com (AWP), with annual report for fiscal year ended October 31, 2025.
• ·Contact: 1-800-522-5465 for attendance or reports.

07-04-2026

Dollar General's 2026 Proxy Statement details increases in non-employee director compensation for fiscal 2026, including Board retainer rising 10.5% to $105,000, Audit Committee Chairperson retainer up 20% to $30,000, and annual equity award value increasing 2.6% to $195,000, to enhance competitiveness per peer data reviewed by Pearl Meyer. Fiscal 2025 actual compensation for directors ranged from $302,650 (e.g., Warren F. Bryant) to $498,724 (Michael M. Calbert), with standard RSU awards valued at $203,166 and Chairman equity at an additional $189,753. All non-employee directors meet NYSE and SEC independence standards, with no material relationships noted, though director pay increases represent a modest cost escalation without declines in other governance metrics.

• ·As of January 30, 2026, unvested RSUs: 2,109 for most directors; 4,821 for Mr. Calbert.
• ·Share ownership guideline: 5x annual cash retainer, achieved by all incumbent non-employee directors or within grace period.
• ·2025 Form 10-K filed March 20, 2026.
• ·Related party transaction policy threshold: exceeds $120,000.

07-04-2026

Alexander's Inc. (ALX) filed a DEFA14A additional proxy statement for its upcoming stockholder meeting, presenting four proposals: (1) election of three director nominees - Thomas R. DiBenedetto, Mandakini Puri, and Russell B. Wight, Jr.; (2) approval of the 2026 Omnibus Stock Plan; (3) non-binding advisory resolution on executive compensation; and (4) ratification of Deloitte & Touche LLP as independent registered public accounting firm. The Board recommends voting 'For' all items. Stockholders can request free paper or email copies of materials by May 7, 2026, via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com.

• ·This is not a votable ballot; follow instructions on reverse side or vote at www.ProxyVote.com.
• ·Include control number in email subject line when requesting materials.
• ·Such other business as may properly come before the meeting or any adjournment thereof.

07-04-2026

Camden Property Trust issued a proxy supplement to its definitive proxy statement for the 2026 Annual Meeting of Shareholders on May 8, 2026, clarifying voting rules for Proposal 4 (Approval of Amended and Restated 2018 Share Incentive Plan) and Proposal 5 (Approval of Amended and Restated 2018 Employee Share Purchase Plan). Each proposal requires the affirmative vote of a majority of shares represented in person or by proxy and entitled to vote, with abstentions treated as votes against and broker non-votes having no effect. Shareholders who have already voted need take no action unless they wish to change their vote.

• ·Annual Meeting scheduled for May 8, 2026 at 9:00 a.m. Central Time.
• ·Proxy revocation: written notice or later-dated proxy to 2800 Post Oak Boulevard, Suite 2700, Houston, Texas 77056, Attention: Corporate Secretary; or vote virtually at meeting.
• ·Investor Relations contact: (800) 922-6336 or (713) 354-2787.
• ·Supplement available at www.proxyvote.com and www.camdenliving.com under SEC Filings.

07-04-2026

INOVIO Pharmaceuticals, Inc.'s 2026 Proxy Statement announces the virtual Annual Meeting of Stockholders on May 20, 2026, at 9:00 a.m. ET, seeking approval on standard matters while highlighting pipeline progress including FDA acceptance of the BLA for INO-3107 in December 2025 with a PDUFA target date of October 30, 2026, and a new collaboration with Akeso Inc. for INO-5412 in glioblastoma. The Board features 75% independent nominees with an average tenure of 9 years and 4 female directors, emphasizing strong governance. No financial declines or flat metrics are reported in the filing.

• ·Annual Meeting: May 20, 2026, 9:00 a.m. ET, virtual at www.virtualshareholdermeeting.com/INO2026
• ·BLA for INO-3107 accepted by FDA in December 2025; PDUFA target October 30, 2026
• ·New position statement published January 2026 in The Laryngoscope recommending HPV-specific immunotherapy including INO-3107
• ·Board meetings in 2025: Audit (45), Compensation (4), Nomination & Corporate Governance (5)

07-04-2026

On April 7, 2026, Rigetti Computing, Inc. announced the deployment of its Cepheus-1-108Q system through the Rigetti Quantum Cloud Services (QCS®) Platform and Amazon Braket, achieving a 99.1% median two-qubit gate fidelity with a gate speed of ~60 ns and 99.9% median single-gate fidelity. This milestone highlights strong technical performance with no reported declines or flat metrics.

• ·Filing includes Exhibit 99.1: Press Release dated April 7, 2026
• ·Item 7.01 information is furnished, not filed

07-04-2026

Tandem Diabetes Care, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on May 20, 2026, to elect nine directors, approve executive compensation on an advisory basis, amend the 2023 Long-Term Incentive Plan to increase authorized shares, approve certificate of incorporation amendments for director removal and officer exculpation, and ratify Ernst & Young LLP as auditors. The company reported strong 2025 performance with worldwide sales of ~$1.015B (up significantly, surpassing $1B milestone) and pump shipments increasing ~5% to more than 126,000 units, including record Q4 sales over $290M; however, short-term cash incentives for NEOs were awarded at 87% of target, reflecting performance below full objectives, and executive compensation benchmarks were reduced to the 50th percentile of peers.

• ·Annual Meeting voting deadline: 11:59 p.m. E.T. on May 19, 2026 for direct shares and May 18, 2026 for Plan shares.
• ·Base salary increases for NEOs ranged 3-8%, with CEO at 8% to reach ~5% below 50th peer percentile.
• ·Long-term equity awards: 50% RSUs and 50% PSUs vesting over three years, tied to TSR and Adjusted EBITDA margin (measured end of 2027).

07-04-2026

Amgen Inc. filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting of Stockholders, to be held virtually on May 19, 2026, at 11:00 A.M. Pacific Time, for holders as of March 20, 2026. Key proposals include electing 12 director nominees (all board-recommended FOR), an advisory vote to approve executive compensation (FOR), ratification of Ernst & Young LLP as auditors for fiscal year ending December 31, 2026 (FOR), and a stockholder proposal requiring an independent board chairman (board recommends AGAINST). Voting must be completed by May 18, 2026 11:59 PM ET for direct shares or May 14, 2026 for Amgen-sponsored plans.

• ·Record date for meeting eligibility: March 20, 2026
• ·Proxy materials request deadline: May 5, 2026
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/AMGN2026
• ·Control numbers referenced for voting: V91788-P49460, V91789-P49460

07-04-2026

Fennec Pharmaceuticals Inc. announced on April 7, 2026, the initiation of an investigator-sponsored study by the University of Arizona Cancer Center to evaluate PEDMARK® (sodium thiosulfate injection) in adolescent, young adult, and adult patients with head and neck and testicular cancers receiving cisplatin. The press release detailing this development is furnished as Exhibit 99.1.

• ·Study focuses on patients receiving cisplatin treatment.

07-04-2026

Meritage Homes Corporation (MTH) filed Definitive Additional Materials (DEFA14A) on April 07, 2026, as part of its proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as Definitive Additional Materials. No financial metrics, performance data, or governance changes are detailed in the provided content.

• ·Filed by the Registrant
• ·Not soliciting material pursuant to §240.14a-12

07-04-2026

ANI Pharmaceuticals, Inc. dismissed EisnerAmper LLP as its independent registered public accounting firm effective April 1, 2026, with approval from the Audit and Finance Committee of the Board of Directors. The company simultaneously appointed Ernst & Young LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no disagreements, reportable events, or qualified audit opinions from EisnerAmper for fiscal years 2024 and 2025.

• ·EisnerAmper's audit reports for fiscal years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications as to uncertainty, audit scope, or accounting principles.
• ·No consultations with EY occurred prior to appointment regarding accounting, auditing, or financial disclosure matters for fiscal years 2024, 2025, or interim period through April 1, 2026.
• ·EisnerAmper provided a letter (Exhibit 16.1) agreeing with the company's statements.